+

WO1998023286A3 - Immunoconjugues comprenant des anticorps monoclonaux humains ou des fragments de ces anticorps, utilises a des fins diagnostiques et therapeutiques - Google Patents

Immunoconjugues comprenant des anticorps monoclonaux humains ou des fragments de ces anticorps, utilises a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
WO1998023286A3
WO1998023286A3 PCT/IT1997/000296 IT9700296W WO9823286A3 WO 1998023286 A3 WO1998023286 A3 WO 1998023286A3 IT 9700296 W IT9700296 W IT 9700296W WO 9823286 A3 WO9823286 A3 WO 9823286A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragments
immunoconjugates
diagnostic
therapy
monoclonal antibodies
Prior art date
Application number
PCT/IT1997/000296
Other languages
English (en)
Other versions
WO1998023286A2 (fr
Inventor
Maria Cristina Thaller
Francesca Berlutti
Laura Selan
Serena Schippa
Claudio Passariello
Stefania Cresti
Gian Maria Rossolini
Paola Cattani
Roberto Sariello
Original Assignee
Isprobi Srl
Maria Cristina Thaller
Francesca Berlutti
Laura Selan
Serena Schippa
Claudio Passariello
Stefania Cresti
Gian Maria Rossolini
Paola Cattani
Roberto Sariello
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isprobi Srl, Maria Cristina Thaller, Francesca Berlutti, Laura Selan, Serena Schippa, Claudio Passariello, Stefania Cresti, Gian Maria Rossolini, Paola Cattani, Roberto Sariello filed Critical Isprobi Srl
Priority to AU51354/98A priority Critical patent/AU5135498A/en
Publication of WO1998023286A2 publication Critical patent/WO1998023286A2/fr
Publication of WO1998023286A3 publication Critical patent/WO1998023286A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention se rapporte à un immunoconjugué, qui est constitué par un premier élément comprenant un anticorps humain ou des fragments de cet anticorps, capables de reconnaître un antigène cible et de se lier spécifiquement à lui, ainsi que par un second élément composé d'un moyen de contraste de détection ou d'une molécule active sur le plan thérapeutique.
PCT/IT1997/000296 1996-11-26 1997-11-26 Immunoconjugues comprenant des anticorps monoclonaux humains ou des fragments de ces anticorps, utilises a des fins diagnostiques et therapeutiques WO1998023286A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU51354/98A AU5135498A (en) 1996-11-26 1997-11-26 Immunoconjugates comprising human monoclonal antibodies or fragments thereof for diagnostic and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM96A000808 1996-11-26
IT96RM000808A ITRM960808A1 (it) 1996-11-26 1996-11-26 Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia

Publications (2)

Publication Number Publication Date
WO1998023286A2 WO1998023286A2 (fr) 1998-06-04
WO1998023286A3 true WO1998023286A3 (fr) 1998-07-30

Family

ID=11404554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1997/000296 WO1998023286A2 (fr) 1996-11-26 1997-11-26 Immunoconjugues comprenant des anticorps monoclonaux humains ou des fragments de ces anticorps, utilises a des fins diagnostiques et therapeutiques

Country Status (3)

Country Link
AU (1) AU5135498A (fr)
IT (1) ITRM960808A1 (fr)
WO (1) WO1998023286A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175617A2 (fr) * 1984-09-13 1986-03-26 Cytogen Corporation Conjugués d'anticorps et d'agent thérapeutique
EP0270340A2 (fr) * 1986-12-05 1988-06-08 Cancer Biologics, Inc. Utilisation d'un conjugué d'anticorps pour la détection de tissu nécrotique malin et pour la thérapie associée
EP0417927A1 (fr) * 1989-08-24 1991-03-20 Immunomedics, Inc. Détection et traitement d'infections en utilisant des immunoconjugués
WO1991007987A1 (fr) * 1989-12-05 1991-06-13 Immunomedics, Inc. Anticorps chimerique de detection et de traitement de lesions infectieuses et inflammatoires
WO1994006448A1 (fr) * 1992-09-16 1994-03-31 The Scripps Research Institute Anticorps monoclonaux neutralisateurs humains contre le virus respiratoire syncytial
WO1995002424A1 (fr) * 1993-07-14 1995-01-26 Nordion International Inc. Localisation et therapie du cancer endocrinien non prostatique au moyen d'agents diriges contre l'antigene specifique de la prostate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175617A2 (fr) * 1984-09-13 1986-03-26 Cytogen Corporation Conjugués d'anticorps et d'agent thérapeutique
EP0270340A2 (fr) * 1986-12-05 1988-06-08 Cancer Biologics, Inc. Utilisation d'un conjugué d'anticorps pour la détection de tissu nécrotique malin et pour la thérapie associée
EP0417927A1 (fr) * 1989-08-24 1991-03-20 Immunomedics, Inc. Détection et traitement d'infections en utilisant des immunoconjugués
WO1991007987A1 (fr) * 1989-12-05 1991-06-13 Immunomedics, Inc. Anticorps chimerique de detection et de traitement de lesions infectieuses et inflammatoires
WO1994006448A1 (fr) * 1992-09-16 1994-03-31 The Scripps Research Institute Anticorps monoclonaux neutralisateurs humains contre le virus respiratoire syncytial
WO1995002424A1 (fr) * 1993-07-14 1995-01-26 Nordion International Inc. Localisation et therapie du cancer endocrinien non prostatique au moyen d'agents diriges contre l'antigene specifique de la prostate

Also Published As

Publication number Publication date
WO1998023286A2 (fr) 1998-06-04
ITRM960808A0 (it) 1996-11-26
ITRM960808A1 (it) 1998-05-26
AU5135498A (en) 1998-06-22

Similar Documents

Publication Publication Date Title
CA2249320A1 (fr) Anticorps humanises glycosyles specifiques des lymphocytes b
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
CA2429027A1 (fr) Anticorps contre le recepteur humain h4-1bb
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
WO2003099196A3 (fr) Anticorps monoclonaux humanises immunomodulateurs servant a traiter une maladie neoplasique ou une immunodeficience
CA2250141A1 (fr) Anticorps monoclonaux de l'antigene membranaire specifique de la prostate
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
WO2004010947A3 (fr) Anticorps humanises contre le 4-1bb humain
WO1999028471A3 (fr) ANTICORPS, NOTAMMENT DES MOLECULES Fv, IMMUNOCONJUGUES PRESENTANT UNE GRANDE AFFINITE DE LIAISON POUR LA MESOTHELINE ET PROCEDES D'UTILISATION CORRESPONDANTS
EP1715045A3 (fr) Anticorps de recombinaison pour thérapie humaine
WO1997019111A3 (fr) Anticorps monoclonaux anti-cd6 et leurs utilisations
AU2559799A (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
WO2001005425A3 (fr) Preparations combinees comprenant des agents antitumoraux
IL126803A (en) Method and composition for reconforming multiepitopic antigens to initiate an immune response
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
WO2002074251A3 (fr) Traitement par anticorps monoclonal du cancer du pancreas
AU7960600A (en) Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
AU3437497A (en) Igg immunoglobulins and f(ab')2 fragments thereof, specific for drugs and metabolites thereof, and their use for detoxification purposes
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
AU641736B2 (en) Delivery of agents
WO1998023286A3 (fr) Immunoconjugues comprenant des anticorps monoclonaux humains ou des fragments de ces anticorps, utilises a des fins diagnostiques et therapeutiques
CA2387383A1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
AU4086397A (en) Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
WO1999043815A3 (fr) Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation
ZA9710391B (en) Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载